Relevant bibliographies by topics / Sulphasalazine / Journal articles
To see the other types of publications on this topic, follow the link: Sulphasalazine.

Journal articles on the topic 'Sulphasalazine'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Sulphasalazine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Sulphasalazine." Reactions Weekly &NA;, no. 969 (September 2003): 14. http://dx.doi.org/10.2165/00128415-200309690-00044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Freeman, Hugh J., Urs P. Steinbrecher, WC Peter Kwan, and Stephanie Ensworth. "Sulphasalazine-Induced Pseudomembranous Colitis." Canadian Journal of Gastroenterology 5, no. 5 (1991): 167–70. http://dx.doi.org/10.1155/1991/420864.

Full text
Abstract:
An 18-year-old female with ankylosing spondylitis developed fever, abdominal pain and diarrhea on two occasions after starting sulphasalazine therapy. Flexible sigmoidoscopy revealed pseudomembranous colitis; fecal cultures were positive forClostridium difficile; andC difficiletoxin assay was positive. Despite the frequent use of sulphasalazine in the management of inflammatory bowel disease, this complication has been apparently rare. Clinicians should be wary of the onset of diarrhea in patients receiving sulphasalazine, whether for inflammatory bowel disease or other conditions.
APA, Harvard, Vancouver, ISO, and other styles
3

Jennings, P. E., R. L. Blandford, and F. D. Rosenthal. "Acute sulphasalazine hepatotoxicity." Postgraduate Medical Journal 62, no. 726 (April 1, 1986): 305–6. http://dx.doi.org/10.1136/pgmj.62.726.305.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rijk, Marno C. M. "Sulphasalazine and Prednisone Compared with Sulphasalazine for Treating Active Crohn Disease." Annals of Internal Medicine 114, no. 6 (March 15, 1991): 445. http://dx.doi.org/10.7326/0003-4819-114-6-445.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bax, D. E., R. S. Amos, D. Situnayake, and B. Mcconkey. "SULPHASALAZINE IN RHEUMATOID ARTHRITIS." Lancet 325, no. 8443 (June 1985): 1450. http://dx.doi.org/10.1016/s0140-6736(85)91878-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

VYSE, T., and A. K. L. SO. "SULPHASALAZINE INDUCED AUTOIMMUNE SYNDROME." Rheumatology 31, no. 2 (1992): 115–16. http://dx.doi.org/10.1093/rheumatology/31.2.115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

McCONKEY, B. "SULPHASALAZINE AND ANKYLOSING SPONDYLITIS." Rheumatology 29, no. 1 (1990): 1–3. http://dx.doi.org/10.1093/rheumatology/29.1.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pullar, T., J. A. Hunter, and H. A. Capell. "SULPHASALAZINE IN RHEUMATOID ARTHRITIS." Lancet 325, no. 8438 (May 1985): 1167. http://dx.doi.org/10.1016/s0140-6736(85)92477-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Feltelius, N., and R. Hallgren. "Sulphasalazine in ankylosing spondylitis." Annals of the Rheumatic Diseases 45, no. 5 (May 1, 1986): 396–99. http://dx.doi.org/10.1136/ard.45.5.396.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Amos, R. S., D. E. Bax, and M. S. Greaves. "Sulphasalazine therapy in RA." Annals of the Rheumatic Diseases 45, no. 5 (May 1, 1986): 439. http://dx.doi.org/10.1136/ard.45.5.439-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Pullar, T., J. A. Hunter, and H. A. Capell. "Sulphasalazine and hepatic transaminases." Annals of the Rheumatic Diseases 46, no. 5 (May 1, 1987): 421. http://dx.doi.org/10.1136/ard.46.5.421-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Parry, S. D., C. Barbatzas, E. T. Peel, and J. R. Barton. "Sulphasalazine and lung toxicity." European Respiratory Journal 19, no. 4 (April 2002): 756–64. http://dx.doi.org/10.1183/09031936.02.00267402.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Domingo, J. J. Sebastian, A. Ventura, V. Pérez Ayala, and D. Castellanos. "Hypersensitivity pneumonitis by sulphasalazine." Allergy 44, no. 7 (October 1989): 522. http://dx.doi.org/10.1111/j.1398-9995.1989.tb04193.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Long, R. "Sulphasalazine and keratoconjunctivitis sicca." Veterinary Record 116, no. 10 (March 9, 1985): 274. http://dx.doi.org/10.1136/vr.116.10.274-b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Burrows, C. "Keratoconjunctivitis sicca and sulphasalazine." Veterinary Record 116, no. 20 (May 18, 1985): 550. http://dx.doi.org/10.1136/vr.116.20.550-b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Bedford, P. "Sulphasalazine and keratoconjunctivitis sicca." Veterinary Record 116, no. 8 (February 23, 1985): 222. http://dx.doi.org/10.1136/vr.116.8.222-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Kanwar, A. J., M. Singh, M. Yunus, and M. S. Belhaj. "Fixed Eruption to Sulphasalazine." Dermatology 174, no. 2 (1987): 104. http://dx.doi.org/10.1159/000248997.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

GOLDING, D. N. "Sulphasalazine for Palindromic Rheumatism." Rheumatology 27, no. 1 (1988): 79. http://dx.doi.org/10.1093/rheumatology/27.1.79.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Peters, F. P., L. G. Engels, and A. M. Moers. "Pneumonitis induced by sulphasalazine." Postgraduate Medical Journal 73, no. 856 (February 1, 1997): 99–100. http://dx.doi.org/10.1136/pgmj.73.856.99.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Quinn, A. G., W. R. Ellis, D. Burn, and N. Cartlidge. "Chorea precipitated by sulphasalazine." BMJ 302, no. 6783 (April 27, 1991): 1025. http://dx.doi.org/10.1136/bmj.302.6783.1025-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

YOUSSEF, P. P., and J. V. BERTOUCH. "Sulphasalazine induced aplastic anaemia." Australian and New Zealand Journal of Medicine 22, no. 4 (August 1992): 391–92. http://dx.doi.org/10.1111/j.1445-5994.1992.tb02161.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Crao, S. S. "Sulphasalazine and gastrointestinal transit." Gut 32, no. 9 (September 1, 1991): 1087. http://dx.doi.org/10.1136/gut.32.9.1087-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Michalowski, A. S. "Sulphasalazine in ulcerative colitis." Gut 33, no. 11 (November 1, 1992): 1582. http://dx.doi.org/10.1136/gut.33.11.1582-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Dwarakanath, A. D., J. Michael, and R. N. Allan. "Sulphasalazine induced renal failure." Gut 33, no. 7 (July 1, 1992): 1006–7. http://dx.doi.org/10.1136/gut.33.7.1006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Price, T. R. "Sensorimotor neuropathy with sulphasalazine." Postgraduate Medical Journal 61, no. 712 (February 1, 1985): 147–48. http://dx.doi.org/10.1136/pgmj.61.712.147.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Siva, A., F. Karaali, F. Karantay, S. Saip, and O. Kantarci. "Sulphasalazine in multiple sclerosis." Journal of Neuroimmunology 56-63 (1995): 51. http://dx.doi.org/10.1016/0165-5728(95)99030-m.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Barnett, K. C., and E. C. Joseph. "Keratoconjunctivitis Sicca in the Dog Following 5-Aminosalicylic Acid Administration." Human Toxicology 6, no. 5 (September 1987): 377–83. http://dx.doi.org/10.1177/096032718700600506.

Full text
Abstract:
1 Keratoconjunctivitis sicca (KCS) is an inflammatory eye condition, affecting the cornea and conjunctiva, caused by a deficiency in the aqueous fraction of tears. The condition is relatively common in the dog with a varied aetiology. A number of drugs have been implicated in the production of KCS in the dog including salicylazosulphapyridine (sulphasalazine). 2 This paper details clinically evident KCS in a 12-month oral toxicity study with 5-aminosalicylic acid (5-ASA), the therapeutically active metabolite of sulphasalazine. 3 The condition was first diagnosed at study week 22 and subsequently progressed both in incidence and severity. There was a distinct sex-difference in the response, with treated females being more affected than males. 4 There was a close correlation between the production of KCS and reduced lacrimation as assessed by the Schirmer tear test. 5 Although sulphasalazine causes KCS in dogs there have been no reports of ocular lesions of this type in man with this drug. It is highly probable that the dog is not a predictive model for man with regard to KCS induction by sulphasalazine or its metabolite 5-ASA.
APA, Harvard, Vancouver, ISO, and other styles
28

Sharma, Vinod K. "Safety Profile of the New 5-ASA Based Compounds." Canadian Journal of Gastroenterology 4, no. 7 (1990): 443–45. http://dx.doi.org/10.1155/1990/345274.

Full text
Abstract:
5-aminosalicylic acid (5-ASA) preparations were anticipated to be and generally are better tolerated than sulphasalazine. Minor side effects such as headache, dizziness, abdominal pain and nausea do occur but are not more frequent than in placebo-treated patients. Approximately 10% of patients thought to be allergic to sulphasalazine are also allergic to 5-ASA. An idiosyncratic reaction with worsening of symptoms can occur. Diarrhea is more common with olsalazine, and it is due to the effect of olsalazine itself on the small bowel. not the 5-ASA component. There are case reports of pancreatitis, pericarditis and bronchospasm, retrosternal chest pain, mild neutropenia, nephrotic syndrome and hair loss associated with 5-ASA treatment. Patients with oligospermia due to sulphasalazine have improved when switched to 5-ASA. 5-ASA enemas can cause local irritation or other effects resulting from enema tip insertion.
APA, Harvard, Vancouver, ISO, and other styles
29

SEIDEMAN, P. "Sulphasalazine Treatment of Psoriatic Arthritis." Rheumatology 29, no. 6 (1990): 491–92. http://dx.doi.org/10.1093/rheumatology/29.6.491-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Winkler, V., and P. Vertes. "Sulphasalazine treatment in rheumatoid arthritis." Annals of the Rheumatic Diseases 49, no. 3 (March 1, 1990): 202. http://dx.doi.org/10.1136/ard.49.3.202-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Pałgan, K., and Z. Bartuzi. "Dress Syndrome Induced by Sulphasalazine." European Journal of Inflammation 12, no. 1 (January 2014): 187–90. http://dx.doi.org/10.1177/1721727x1401200118.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

ASTBURY, C., and A. J. TAGGART. "Acetylation, Sulphasalazine and its Effects." Rheumatology 26, no. 3 (1987): 229–30. http://dx.doi.org/10.1093/rheumatology/26.3.229-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

PEARS, J. S., and K. D. MORLEY. "Fatal Hypersensitivity Reaction to Sulphasalazine." Rheumatology 28, no. 3 (1989): 274–75. http://dx.doi.org/10.1093/rheumatology/28.3.274.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Barbour, V. M., and P. F. Williams. "Nephrotic syndrome associated with sulphasalazine." BMJ 301, no. 6755 (October 6, 1990): 818. http://dx.doi.org/10.1136/bmj.301.6755.818-b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Suresh, Resmy, Sanjay Gupta, and Rosh Sathananthan. "Sulphasalazine Induced Three-Week Syndrome." JCR: Journal of Clinical Rheumatology 15, no. 6 (September 2009): 311–12. http://dx.doi.org/10.1097/rhu.0b013e3181bbbcea.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Dubey, S., and A. O. Adebajo. "Lymphoproliferative disorder due to sulphasalazine." Case Reports 2009, mar08 1 (March 17, 2009): bcr0620080038. http://dx.doi.org/10.1136/bcr.06.2008.0038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

MONGEY, A. B., and E. V. HESS. "Sulphasalazine-induced Systemic Lupus Erythematosus." Rheumatology 33, no. 8 (1994): 789. http://dx.doi.org/10.1093/rheumatology/33.8.789-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Meenan, J. "Co-carcinogenic effect of sulphasalazine." British Journal of Cancer 68, no. 5 (November 1993): 1043–44. http://dx.doi.org/10.1038/bjc.1993.477.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Brooks, H., H. G. Taylor, and F. E. Nichol. "The three week sulphasalazine syndrome." Clinical Rheumatology 11, no. 4 (December 1992): 566–68. http://dx.doi.org/10.1007/bf02283121.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Ogle, C. W., C. H. Cho, and S. Dai. "Sulphasalazine and experimental stress ulcers." Agents and Actions 17, no. 2 (December 1985): 153–57. http://dx.doi.org/10.1007/bf01966585.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Freeman, H. J. "Sulphasalazine-induced forms of colitis." Inflammopharmacology 2, no. 3 (September 1993): 301–5. http://dx.doi.org/10.1007/bf02660621.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Deltenre, P., A. Berson, P. Marcellin, C. Degott, M. Biour, and D. Pessayre. "Mesalazine (5-aminosalicylic acid) induced chronic hepatitis." Gut 44, no. 6 (June 1, 1999): 886–88. http://dx.doi.org/10.1136/gut.44.6.886.

Full text
Abstract:
BACKGROUNDTreatment of ulcerative colitis or Crohn’s disease with sulphasalazine causes several adverse effects, including hepatitis. Sulphasalazine is cleaved by colonic bacteria into 5-aminosalicylic acid and sulphapyridine. Received wisdom was that 5-aminosalicylic acid was topically active, whereas sulphapyridine was absorbed and caused immunoallergic side effects. Mesalazine, a slow release formulation of 5-aminosalicylic acid, was expected to be a safe alternative. However, several cases of acute hepatitis have been reported.CASE REPORTA 65 year old man had increased liver enzymes, anti-nuclear and anti-smooth muscle autoantibodies and IgG levels, and lesions of chronic hepatitis after 21 months of mesalazine treatment. Although liver dysfunction had been identified eight months earlier, simvastatin rather than mesalazine had been withdrawn, without any improvement. In contrast, liver enzyme and IgG levels became normal and autoantibodies disappeared after discontinuation of mesalazine administration.CONCLUSIONContrary to initial expectations, mesalazine can cause most of the sulphasalazine induced adverse effects, and hepatic side effects may be almost as frequent. When liver dysfunction occurs, mesalazine administration should be discontinued to avoid the development of chronic hepatitis and liver fibrosis.
APA, Harvard, Vancouver, ISO, and other styles
43

Gibson, P. R., and D. P. Jewell. "Sulphasalazine and Derivatives, Natural Killer Activity and Ulcerative Colitis." Clinical Science 69, no. 2 (August 1, 1985): 177–84. http://dx.doi.org/10.1042/cs0690177.

Full text
Abstract:
1. The effects of sulphasalazine, 5-aminosalicylic acid (5-ASA), sulphapyridine and azodisalicylic acid (ADS) in vitro on the natural killer (NK) activity of peripheral blood mononuclear cells (MNC) have been examined and compared with those of the lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA) and the cyclooxygenase inhibitor, indomethacin. 2. Sulphasalazine, sulphapyridine and ADS inhibited NK activity with 50% inhibitory concentrations (IC50) of 0.7, 2.5 and 4.0 mmol/l respectively. The effect was rapidly reversible. In contrast, 5-ASA minimally inhibited NK activity at 50 mmol/l only. 3. NDGA potently inhibited NK activity (IC50 27 μmol/l) but this was only partly reversible in short term incubations. Indomethacin had no effect at concentrations less than those inhibiting cyclo-oxygenase activity (1-10 μmol/l) but potently and reversibly inhibited NK activity at or above 25 μmol/l. 4. The inhibitory effects observed were unlikely to be due to direct toxicity of effector cells as 5-ASA, sulphapyridine and ADS had no effect on the viability of peripheral blood MNC, whereas NDGA and indomethacin lysed MNC only at maximal concentrations tested. Though sulphasalazine produced MNC lysis at and above 1 mmol/l, the rapid reversibility of the inhibition of NK activity at 1 mmol/l suggested that lysis of NK cells contributed little to the suppressive effect at this concentration. 5. The disparity of the therapeutic efficacy and effects on NK activity of sulphasalazine and its derivatives in vitro may suggest that NK activity is not a major pathogenic mechanism in ulcerative colitis. Any inhibitory effect on cellular immune function of indomethacin does not necessarily reflect an effect of cyclo-oxygenase inhibition.
APA, Harvard, Vancouver, ISO, and other styles
44

Miner, PB, and WL Biddle. "Maintaining Remission in Distal Ulcerative Colitis and Ulcerative Proctitis." Canadian Journal of Gastroenterology 4, no. 7 (1990): 476–80. http://dx.doi.org/10.1155/1990/864194.

Full text
Abstract:
Maintenance of remission is an important consideration in the medical care of patients with ulcerative colitis. The relapse rate is high when medications are discontinued. Many types of medications have been investigated for potential efficacy of maintaining remission. This paper reviews the literature on maintenance therapy for both distal and universal ulcerative colitis. Sulphasalazine is the drug of choice since il is effective and relatively low m cost. 5-aminosalicylic acid (5-ASA) derivatives, both oral and rectal forms, are also effective. Other medications such as metronidazole, cromolyn sodium and prednisone have nor been shown to be effective maintenance therapy. Strategies for maintenance are outlined and include possible regimens with 5-ASA enemas. While 1 g of 5-ASA is effective, the long term relapse rate is similar co that seen with sulphasalazine. Patients capered co 1 g 5-ASA enemas have a good chance of maintaining remission if the colitis does not flare within the first few months, because most colites will flare up early on. Other possible regimens include intermittent enemas, eg, every other night or every third night. Patients in remission can be safely maintained in remission with sulphasalazine or one of its 5-ASA derivatives.
APA, Harvard, Vancouver, ISO, and other styles
45

Elsakka, Elsayed, Gamil Abd-Allah, Ahmed Abulsoud, Ahmed Mansour, and Sayed Raheem. "Sulphasalazine Prevents Fibrosis; Relevance of TGFβRI." International Journal of Biochemistry Research & Review 12, no. 3 (January 10, 2016): 1–10. http://dx.doi.org/10.9734/ijbcrr/2016/25627.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Hoult, J. R. S. "Pharmacological and Biochemical Actions of Sulphasalazine." Drugs 32, Supplement 1 (1986): 18–26. http://dx.doi.org/10.2165/00003495-198600321-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Ireland, A., and D. P. Jewell. "Olsalazine in Patients Intolerant of Sulphasalazine." Scandinavian Journal of Gastroenterology 23, sup148 (January 1988): 101–3. http://dx.doi.org/10.3109/00365528809101561.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Ireland, A., and D. P. Jewell. "Olsalazine in Patients Intolerant of Sulphasalazine." Scandinavian Journal of Gastroenterology 22, no. 9 (January 1987): 1038–40. http://dx.doi.org/10.3109/00365528708991953.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

PETTERSSON, T., M. GRIPENBERG, G. MOLANDER, and C. FRIMAN. "Severe Immunological Reaction induced by Sulphasalazine." Rheumatology 29, no. 3 (1990): 239–40. http://dx.doi.org/10.1093/rheumatology/29.3.239-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Riley, S. A., P. J. Flegg, and B. K. Mandal. "CONTACT LENS STAINING DUE TO SULPHASALAZINE." Lancet 327, no. 8487 (April 1986): 972. http://dx.doi.org/10.1016/s0140-6736(86)91071-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography